Emerald Mutual Fund Advisers Trust cut its position in Intrexon Corp. (NYSE:XON) by 28.7% during the second quarter, Holdings Channel reports. The fund owned 194,837 shares of the company’s stock after selling 78,473 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Intrexon Corp. were worth $4,795,000 as of its most recent filing with the SEC.
Several other institutional investors also recently modified their holdings of XON. Legal & General Group Plc boosted its position in shares of Intrexon Corp. by 3.4% in the first quarter. Legal & General Group Plc now owns 3,788 shares of the company’s stock worth $128,000 after buying an additional 126 shares during the last quarter. BlackRock Inc. boosted its stake in Intrexon Corp. by 321.0% in the first quarter. BlackRock Inc. now owns 5,780 shares of the company’s stock worth $195,000 after buying an additional 4,407 shares in the last quarter. Cacti Asset Management LLC acquired a new stake in Intrexon Corp. during the second quarter worth $246,000. Alpine Partners VI LLC acquired a new stake in Intrexon Corp. during the first quarter worth $292,000. Finally, Aperio Group LLC acquired a new stake in Intrexon Corp. during the first quarter worth $299,000. 84.05% of the stock is owned by institutional investors and hedge funds.
Shares of Intrexon Corp. (NYSE:XON) traded up 4.07% on Friday, reaching $29.69. The company’s stock had a trading volume of 1,387,993 shares. The firm has a 50 day moving average of $27.33 and a 200 day moving average of $28.14. Intrexon Corp. has a 52-week low of $18.52 and a 52-week high of $43.76. The company’s market cap is $3.51 billion.
Intrexon Corp. (NYSE:XON) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.16. The company earned $52.50 million during the quarter, compared to the consensus estimate of $53.78 million. Intrexon Corp. had a negative net margin of 96.65% and a negative return on equity of 19.00%. The company’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.37) earnings per share. Analysts predict that Intrexon Corp. will post ($1.36) earnings per share for the current year.
A number of equities research analysts recently weighed in on XON shares. Vetr raised Intrexon Corp. from a “strong sell” rating to a “buy” rating and set a $27.01 price target for the company in a report on Thursday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $57.00 price target on shares of Intrexon Corp. in a report on Wednesday, June 29th. Griffin Securities reaffirmed a “buy” rating and set a $55.00 price target on shares of Intrexon Corp. in a report on Tuesday, August 16th. Wunderlich reaffirmed a “buy” rating and set a $50.00 price target on shares of Intrexon Corp. in a report on Thursday, July 7th. Finally, Zacks Investment Research cut Intrexon Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 12th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $41.71.
In related news, SVP Nir Nimrodi purchased 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The stock was acquired at an average cost of $26.12 per share, for a total transaction of $104,480.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 55.10% of the stock is owned by corporate insiders.
About Intrexon Corp.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp. (NYSE:XON).
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.